You are viewing the site in preview mode

Skip to main content

COVID-19 trial protocols

Research into COVID-19 is exploding, as it needs to, and this includes randomised trials.  Between 23rd of January and 8th March 2020 there were 382 registered COVID-19 trials. Almost all of those were in China but the virus is now global and trials will move with it.

Researchers need to know about these trials, and they need to know quickly.  

Trials are therefore implementing a new, simplified process for handling COVID-19 trial protocols which is must faster and much simpler for authors. Please visit trialsjournal.biomedcentral.com/covid-19 for more information.

Page 2 of 4

  1. We aimed to test our hypothesis that traditional Japanese (Kampo) medicine, hochuekkito (Hochu-ekki-to: HET) has a preventive effect for the symptoms on COVID-19.

    Authors: Takao Namiki, Shin Takayama, Ryutaro Arita, Tadashi Ishii, Mosaburo Kainuma, Toshiaki Makino, Masaru Mimura, Tetsuhiro Yoshino, Tatsuya Nogami, Makoto Arai, Juichi Sato, Koichiro Tanaka, Hajime Nakae, Hidetoshi Igari, Yoshihito Ozawa, Yuki Shiko…

    Citation: Trials 2021 22:23

    Content type: Letter

    Published on:

  2. The primary objective is to determine which of two interventions: 1) an eight week, online, home-based, supervised, group rehabilitation programme (REGAIN); or 2) a single online session of advice (best-practi...

    Authors: Gordon McGregor, Harbinder Sandhu, Julie Bruce, Bartholomew Sheehan, David McWilliams, Joyce Yeung, Christina Jones, Beatriz Lara, Jessica Smith, Chen Ji, Elaine Fairbrother, Stuart Ennis, Peter Heine, Sharisse Alleyne, Jonathan Guck, Emma Padfield…

    Citation: Trials 2021 22:8

    Content type: Letter

    Published on:

    The Correction to this article has been published in Trials 2021 22:96

  3. We will evaluate the efficacy and safety of Ivermectin in patients with mild and moderately severe COVID-19.

    Authors: Fatemeh Sadat Hosseini, Alireza Malektojari, Sara Ghazizadeh, Mehdi Hassaniazad, Parivash Davoodian, Habib Dadvand, Amin Reza Nikpoor, Sara Nikoofal-Sahlabadi, Sara Kahoori, Mojtaba Sepandi, Soheil Hassanipour and Mohammad Fathalipour

    Citation: Trials 2021 22:4

    Content type: Letter

    Published on:

  4. To investigate the efficacy and safety of repurposed antiprotozoal and antiretroviral drugs, nitazoxanide and atazanavir/ritonavir, in shortening the time to clinical improvement and achievement of SARS-CoV-2 ...

    Authors: Adeniyi Olagunju, Adeola Fowotade, Ajibola Olagunoye, Temitope Olumuyiwa Ojo, Bolanle Olufunlola Adefuye, Adeniyi Francis Fagbamigbe, Akindele Olupelumi Adebiyi, Omobolanle Ibitayo Olagunju, Olabode Taiwo Ladipo, Abdulafeez Akinloye, Babatunde Ayodeji Adeagbo, Adedeji Onayade, Oluseye Oladotun Bolaji, Christian Happi, Steve Rannard and Andrew Owen

    Citation: Trials 2021 22:3

    Content type: Letter

    Published on:

  5. Conestat alfa, a recombinant human C1 esterase inhibitor, is a multi-target inhibitor of inflammatory cascades including the complement, the kinin-kallikrein and the contact activation system. The study object...

    Authors: Pascal Urwyler, Panteleimon Charitos, Stephan Moser, Ingmar A. F. M. Heijnen, Marten Trendelenburg, Reto Thoma, Johannes Sumer, Adrián Camacho-Ortiz, Marcelo R. Bacci, Lars C. Huber, Melina Stüssi-Helbling, Werner C. Albrich, Parham Sendi and Michael Osthoff

    Citation: Trials 2021 22:1

    Content type: Letter

    Published on:

  6. With the lack of effective therapy, chemoprevention, and vaccination against SARS-CoV-2, focusing on the immediate repurposing of existing drugs gives hope of curbing the COVID-19 pandemic. A recent unbiased g...

    Authors: Cédric Annweiler, Mélinda Beaudenon, Jennifer Gautier, Romain Simon, Vincent Dubée, Justine Gonsard and Elsa Parot-Schinkel

    Citation: Trials 2020 21:1031

    Content type: Study protocol

    Published on:

  7. We aimed to test our expectation that additional administration of Traditional Chinese medicine (TCM), maxingshigan-weijing decoction, is more effective in the management of COVID-19 patients compared to those...

    Authors: Congcong Zeng, Zhengzhong Yuan, Xiaoqiong Pan, Jizhou Zhang, Jiahui Zhu, Fan Zhou, Zhuocheng Shan, Ye Yuan, Ren Ye and Jinguo Cheng

    Citation: Trials 2020 21:1029

    Content type: Letter

    Published on:

  8. This study aims to investigate the efficacy of curcumin-piperine co-supplementation on disease duration, severity and clinical symptoms, and inflammatory mediators in patients with coronavirus (COVID-19).

    Authors: Mahsa Miryan, Mohammad Bagherniya, Amirhossein Sahebkar, Davood Soleimani, Mohammad Hossein Rouhani, Bijan Iraj and Gholamreza Askari

    Citation: Trials 2020 21:1027

    Content type: Letter

    Published on:

  9. SARS-Cov-2 virus preferentially binds to the Angiotensin Converting Enzyme 2 (ACE2) on alveolar epithelial type II cells, initiating an inflammatory response and tissue damage which may impair surfactant synth...

    Authors: Ahilanandan Dushianthan, Howard Clark, Jens Madsen, Robin Mogg, Lewis Matthews, Lee Berry, Jorge Bernardino de la Serna, James Batchelor, David Brealey, Tracy Hussell, Joanna Porter, Ratko Djukanovic, Martin Feelisch, Anthony Postle and Michael P. W. Grocott

    Citation: Trials 2020 21:1014

    Content type: Letter

    Published on:

  10. This interventional study will investigate the effect of daily use of a mindfulness app on measures of participant anxiety, well-being, and perceived outlook during the COVID-19 pandemic, by comparing pre-inte...

    Authors: Katherine T. O’Donnell, Melanie Dunbar and Diana L. Speelman

    Citation: Trials 2020 21:1006

    Content type: Letter

    Published on:

  11. The peak of the global COVID-19 pandemic has not yet been reached, and many countries face the prospect of a second wave of infections before effective vaccinations will be available. After an initial phase of...

    Authors: T. Vanassche, M. M. Engelen, Q. Van Thillo, J. Wauters, J. Gunst, C. Wouters, C. Vandenbriele, S. Rex, L. Liesenborghs, A. Wilmer, P. Meersseman, G. Van den Berghe, D. Dauwe, G. Verbeke, M. Thomeer, T. Fivez…

    Citation: Trials 2020 21:1005

    Content type: Study protocol

    Published on:

    The Correction to this article has been published in Trials 2020 21:1033

  12. A severe epidemic of COVID-19 has broken out in China and has become a major global public health event. We focus on the Acute Respiratory Distress Syndrome (ARDS)-like changes and overactivation of Th17 cells...

    Authors: Panpan Liu, Zhijun Huang, Mingzhu Yin, Chun Liu, Xiang Chen, Pinhua Pan and Yehong Kuang

    Citation: Trials 2020 21:999

    Content type: Letter

    Published on:

  13. This study aims to assess the effect of propolis supplementation on clinical symptoms in patients with coronavirus (COVID-19).

    Authors: Mahsa Miryan, Davood Soleimani, Leila Dehghani, Karim Sohrabi, Farzin Khorvash, Mohammad Bagherniya, Sayed Mazaher Sayedi and Gholamreza Askari

    Citation: Trials 2020 21:996

    Content type: Letter

    Published on:

  14. Patients with COVID-19 and hypoxaemia despite conventional low-flow oxygen therapy are often treated with high-flow nasal cannula (HFNC) in line with international guidelines. Oxygen delivery by helmet continu...

    Authors: Jonas Tverring, Anna Åkesson and Niklas Nielsen

    Citation: Trials 2020 21:994

    Content type: Study protocol

    Published on:

  15. Since December 2019, the outbreak of coronavirus pneumonia was observed in China and quickly propagate in all of the world. Nowadays, many trials are underway on this disease in which the efficacy of various t...

    Authors: Maryam Azimi and Fatemeh Sadat Hasheminasab

    Citation: Trials 2020 21:978

    Content type: Study protocol

    Published on:

  16. Patients with diabetes are - compared to people without diabetes - at increased risk of worse outcomes from COVID-19 related pneumonia during hospitalization. We aim to investigate whether telemetric continuou...

    Authors: Carina Kirstine Klarskov, Birgitte Lindegaard, Ulrik Pedersen-Bjergaard and Peter Lommer Kristensen

    Citation: Trials 2020 21:968

    Content type: Letter

    Published on:

  17. To assess the efficacy of ivermectin in addition to standard treatment compared to standard treatment alone in reducing hospitalizations in the COVID-19 patient population.

    Authors: Julio Vallejos, Rodrigo Zoni, Maria Bangher, Silvina Villamandos, Angelina Bobadilla, Fabian Plano, Claudia Campias, Evangelina Chaparro Campias, Fernando Achinelli, Hector A. Guglielmone, Jorge Ojeda, Fernanda Medina, Diego Farizano Salazar, Gerardo Andino, Natalia E. Ruiz Diaz, Pablo Kawerin…

    Citation: Trials 2020 21:965

    Content type: Letter

    Published on:

  19. To evaluate a therapeutic role for omega-3 fatty acid supplementation in the treatment of olfactory dysfunction associated with COVID-19 infection

    Authors: David Lerner, Katherine Garvey, Annie Arrighi-Allisan, Andrey Filimonov, Peter Filip, Katherine Liu, Sen Ninan, Madeleine Schaberg, Patrick Colley, Anthony Del Signore, Satish Govindaraj and Alfred Marc Iloreta

    Citation: Trials 2020 21:942

    Content type: Letter

    Published on:

  20. 1. To compare the effectiveness of four different surveillance strategies in detecting COVID-19 within the homeless shelter population.

    Authors: Timothy O’Shea, Lawrence Mbuagbaw, Vaibhav Mokashi, David Bulir, Jodi Gilchrist, Nicole Smieja, Sylvia Chong, Sarah Marttala, Valentina Vera, Anna Cvetkovic and Marek Smieja

    Citation: Trials 2020 21:941

    Content type: Letter

    Published on:

  21. To assess the effect of prone positioning therapy on intubation rate in awake patients with COVID-19 and acute respiratory failure.

    Authors: Miguel Á. Ibarra-Estrada, Miguel Marín-Rosales, Roxana García-Salcido, Sara A. Aguirre-Díaz, Alexandra Vargas-Obieta, Quetzalcóatl Chávez-Peña, José A. López-Pulgarín, Julio C. Mijangos-Méndez and Guadalupe Aguirre-Avalos

    Citation: Trials 2020 21:940

    Content type: Letter

    Published on:

  22. The GETAFIX trial will test the hypothesis that favipiravir is a more effective treatment for COVID-19 infection in patients who have early stage disease, compared to current standard of care. This study will ...

    Authors: Catherine R. Hanna, Kevin G. Blyth, Glenn Burley, Samantha Carmichael, Carol Evans, Samantha Hinsley, Ibrahim Khadra, Saye Khoo, Liz-Anne Lewsley, Robert R. Jones, Raman Sharma, Andrea Taladriz-Sender, Emma C. Thomson and Janet T. Scott

    Citation: Trials 2020 21:935

    Content type: Letter

    Published on:

  23. Zilucoplan (complement C5 inhibitor) has profound effects on inhibiting acute lung injury post COVID-19, and can promote lung repair mechanisms that lead to improvement in lung oxygenation parameters. The purp...

    Authors: Jozefien Declercq, Cedric Bosteels, Karel Van Damme, Elisabeth De Leeuw, Bastiaan Maes, Ans Vandecauter, Stefanie Vermeersch, Anja Delporte, Bénédicte Demeyere, Marnik Vuylsteke, Marianna Lalla, Trevor Smart, Laurent Detalle, René Bouw, Johannes Streffer, Thibo Degeeter…

    Citation: Trials 2020 21:934

    Content type: Letter

    Published on:

  24. Primary Objective: To determine the feasibility of delivering a protocolised, remote, online, Eye Movement Desensitisation and Reprocessing (EMDR) intervention, within 12-weeks of hospital discharge, for adult su...

    Authors: Andrew Bates, Sophie Rushbrook, Elan Shapiro, Michael Grocott and Rebecca Cusack

    Citation: Trials 2020 21:929

    Content type: Letter

    Published on:

  25. The primary objective is to test if heparin added to a standard regional anticoagulation protocol based on citrate is able to reduce dialysis circuit losses by clotting without increasing the risk of thrombocy...

    Authors: Paulo Ricardo Gessolo Lins, Claudia Coimbra César de Albuquerque, Camila Fernandes Assis, Bruna Cristine Duarte Rodrigues, Beatriz Pinto e Siqueira Campos, Eduardo de Oliveira Valle, Carla Paulina Sandoval Cabrera, Jeison de Oliveira Gois, Gabriela Cardoso Segura, Fernando Louzada Strufaldi, Lorena Catelan Mainardes, Rayra Gomes Ribeiro, Daniela Del Pilar Via Reque Cortes, Luciana Gil Lutf, Márcia Fernanda Arantes de Oliveira, Gabriel Teixeira Montezuma Sales…

    Citation: Trials 2020 21:920

    Content type: Letter

    Published on:

  26. Assessing the effect of surfactant on clinical outcome in patients with COVID-19 under mechanical ventilation

    Authors: Ali Dabbagh, Samira Rajaei, Mehdi Ghahremani, Mohammad Fathi, Nilofar Massoudi, Sasan Tavana, Kamal Fani, Navid Nooraee, Nasser Malekpour Alamdari, Sara Besharat, Arash Najafi Abrandabadi, Ali Pirsalehi and Mohammad Ali Khabiri Khatiri

    Citation: Trials 2020 21:919

    Content type: Letter

    Published on:

  27. - To describe the evolution of the SARS-CoV-2 salivary viral load of patients infected with Covid-19, performing 7 days of tri-daily mouthwashes with and without antivirals.

    Authors: Florence Carrouel, Stéphane Viennot, Martine Valette, Jean-Marie Cohen, Claude Dussart and Denis Bourgeois

    Citation: Trials 2020 21:906

    Content type: Letter

    Published on:

  28. The aim of this trial is to investigate the safety and clinical efficacy of passive immunization therapy through Hyperimmune anti-COVID-19 Intravenous Immunoglobulin (C-IVIG: 5% liquid formulation), on severe ...

    Authors: Shaukat Ali, Shobha Luxmi, Fatima Anjum, Sheikh Muhammad Muhaymin, Syed Muneeb Uddin, Ayesha Ali, Mir Rashid Ali, Sohaib Tauheed, Mujtaba Khan, Mohsin Bajwa, Saif Ullah Baig, Elisha Shalim, Iqra Ahmed, Abdul Samad Khan and Saeed Quraishy

    Citation: Trials 2020 21:905

    Content type: Letter

    Published on:

  29. The selected combination was based on limited evidence clinically and in vitro on the efficacy of the Favipiravir and Hydroxychloroquine in SARS-CoV-2. The two medications were listed in many guidelines as tre...

    Authors: Mohammad Bosaeed, Ebrahim Mahmoud, Mohammad Hussein, Ahmad Alharbi, Abdulrahman Alsaedy, Adel Alothman, Majed Aljeraisy, Hajar Alqahtani, Marwan Nashabat, Badriah Almutairi, Manar Almaghaslah, Omar Aldibasi, Sameera AlJohani, Abderrezak Bouchama, Yaseen Arabi and Ahmad Alaskar

    Citation: Trials 2020 21:904

    Content type: Letter

    Published on:

  30. To assess the impact of adding statin (atorvastatin) and/or aspirin on clinical deterioration in patients infected with SARS-CoV-2 who require hospitalisation. The safety of these drugs in COVID-19 patients wi...

    Authors: Nirmal Ghati, Ambuj Roy, Sushma Bhatnagar, Sumit Bhati, Sudha Bhushan, Manjit Mahendran, Abhishek Thakur, Pawan Tiwari, Tanima Dwivedi, Kalaivani Mani, Ritu Gupta, Anant Mohan, Rakesh Garg, Anita Saxena, Randeep Guleria and Siddharthan Deepti

    Citation: Trials 2020 21:902

    Content type: Letter

    Published on:

  31. Primary Objective: To evaluate the efficacy and safety of oral administration of imatinib combined with the Best Conventional Care (BCC) versus placebo plus BCC in hospitalized patients with COVID-19.

    Authors: Ashkan Emadi, Joel V. Chua, Rohit Talwani, Søren M. Bentzen and John Baddley

    Citation: Trials 2020 21:897

    Content type: Letter

    Published on:

  32. The primary objectives of this study are to determine efficacy of Siddha medicine, Kabasura kudineer in reduction of SARS-CoV-2 viral load and reducing the onset of symptoms in asymptomatic COVID-19 when compared...

    Authors: S. Natarajan, C. Anbarasi, P. Sathiyarajeswaran, P. Manickam, S. Geetha, R. Kathiravan, P. Prathiba, M. Pitchiahkumar, P. Parthiban, K. Kanakavalli and P. Balaji

    Citation: Trials 2020 21:892

    Content type: Letter

    Published on:

  33. In this study, we investigate the effect of boron-containing compounds and oleoylethanolamide supplementation on the recovery trend in patients with COVID-19.

    Authors: Helda Tutunchi, Majid Mobasseri, Samira Pourmoradian, Hamid Soleimanzadeh, Behnam Kafil, Neda Akbari, Alireza Monshikarimi and Alireza Ostadrahimi

    Citation: Trials 2020 21:890

    Content type: Letter

    Published on:

  34. We will evaluate the efficacy and safety of favipiravir and interferon beta-1a compared to lopinavir/ritonavir and interferon beta-1a in patients with confirmed COVID-19, who are moderately ill.

    Authors: Mehdi Hassaniazad, Ali Bazram, Soheil Hassanipour and Mohammad Fathalipour

    Citation: Trials 2020 21:886

    Content type: Letter

    Published on:

  35. General: To assess the safety, efficacy and dose response of convalescent plasma (CP) transfusion in severe COVID-19 patients

    Authors: Fazle Rabbi Chowdhury, Ashraful Hoque, Forhad Uddin Hasan Chowdhury, Md. Ruhul Amin, Abdur Rahim, M. Mujibur Rahman, Rubina Yasmin, Md. Robed Amin, Md. Titu Miah, Md. Abul Kalam and Md. Sayedur Rahman

    Citation: Trials 2020 21:883

    Content type: Letter

    Published on:

  36. We will evaluate the efficacy and safety of Melatonin, compared to the standard therapeutic regimen on clinical symptoms and serum inflammatory parameters in patients with confirmed COVID-19, who are moderatel...

    Authors: Ava Ziaei, Parivash Davoodian, Habib Dadvand, Omid Safa, Soheil Hassanipour, Mahmoud Omidi, Moein Masjedi, Fahime Mahmoudikia, Bahareh Rafiee and Mohammad Fathalipour

    Citation: Trials 2020 21:882

    Content type: Letter

    Published on:

  37. The BCG vaccine, widely used in Brazil in new-borns, induces adjuvant protection for several diseases, including childhood virus infections. BCG activates monocytes and innate memory NK cells which are crucial...

    Authors: Ana Paula Junqueira-Kipnis, Laura Raniere Borges dos Anjos, Lília Cristina de Souza Barbosa, Adeliane Castro da Costa, Kellen Christina Malheiros Borges, Amanda da Rocha Oliveira Cardoso, Kaio Mota Ribeiro, Sarah Brena Aparecida Rosa, Carine de Castro Souza, Rogério Coutinho das Neves, Guylherme Saraiva, Sueli Meira da Silva, Erika Aparecida Silveira, Marcelo Fouad Rabahi, Marcus Barreto Conte and André Kipnis

    Citation: Trials 2020 21:881

    Content type: Letter

    Published on:

    The Correction to this article has been published in Trials 2020 21:967

  38. We will investigate the effectiveness of high dose Interferon Beta 1a, compared to low dose Interferon Beta 1a (the base therapeutic regimen) in COVID-19 Confirmed Cases (Either RT-PCR or CT Scan Confirmed) wi...

    Authors: Ilad Alavi Darazam, Firouze Hatami, Mohammad Mahdi Rabiei, Mohamad Amin Pourhoseingholi, Omid Moradi, Shervin Shokouhi, Mohammad Reza Hajesmaeili, Minoosh Shabani and Seyed Sina Naghibi Irvani

    Citation: Trials 2020 21:880

    Content type: Letter

    Published on:

  39. To investigates the effectiveness of curcumin-containing Nanomicelles as a therapeutic supplement in the treatment of patients with COVID-19 and its effect on immune responses balance changes following treatment.

    Authors: Mehdi Hassaniazad, Behnaz Rahnama Inchehsablagh, Hossein Kamali, Abdolali Tousi, Ebrahim Eftekhar, Mahmoud Reza Jaafari, Mohammad Fathalipour, Sara Nikoofal-Sahlabadi, Hamed Gouklani, Hesam Alizade and Amin Reza Nikpoor

    Citation: Trials 2020 21:876

    Content type: Letter

    Published on:

  40. The primary objective is to demonstrate that COVID-19 convalescent plasma (CCP) prevents progression to severe pneumonia in elderly COVID-19 pneumonia patients with chronic comorbidities.

    Authors: Luciana Teofili, Raffaele Landolfi, Antonella Cingolani, Andrea Antinori, Jacopo Vecchiet, Maurizio Sanguinetti, Antonio Gasbarrini, Tina Pasciuto, Nicoletta Orlando and Silvia Lamonica

    Citation: Trials 2020 21:875

    Content type: Letter

    Published on:

  41. The acknowledgment of the mental health toll of the COVID-19 epidemic in healthcare workers has increased considerably as the disease evolved into a pandemic status. Indeed, high prevalence rates of depression...

    Authors: Luisa Weiner, Fabrice Berna, Nathalie Nourry, François Severac, Pierre Vidailhet and Amaury C. Mengin

    Citation: Trials 2020 21:870

    Content type: Study protocol

    Published on:

  42. 1. To compare the safety and efficacy of Hydroxychloroquine with Ribavirin and standard treatment in patients with non-severe COVID-19 infection

    Authors: Prasan Kumar Panda, Arkapal Bandyopadhyay, Budha Charan Singh, Bikram Moirangthem, Gaurav Chikara, Sarama Saha and Yogesh Arvind Bahurupi

    Citation: Trials 2020 21:866

    Content type: Letter

    Published on:

  43. To evaluate the efficacy of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac in symptomatic individuals, with virological confirmation of COVID-19, two weeks after the completion of...

    Authors: Ricardo Palacios, Elizabeth González Patiño, Roberta de Oliveira Piorelli, Monica Tilli Reis Pessoa Conde, Ana Paula Batista, Gang Zeng, Qianqian Xin, Esper G. Kallas, Jorge Flores, Christian F. Ockenhouse and Christopher Gast

    Citation: Trials 2020 21:853

    Content type: Letter

    Published on:

  45. Primary objective: To determine the efficacy of a candidate antiviral on time to virological cure compared to standard of care within 14 days of randomisation

    Authors: James H. McMahon, Jillian S. Y. Lau, Janine Roney, Benjamin A. Rogers, Jason Trubiano, Joseph Sasadeusz, James S. Molton, Bradley Gardiner, Sue J. Lee, Jennifer F. Hoy, Allen Cheng and Anton Y. Peleg

    Citation: Trials 2020 21:847

    Content type: Letter

    Published on:

  46. To assess the efficacy of several repurposed drugs to prevent hospitalisation or death in patients aged 65 or more with recent symptomatic SARS-CoV-2 infection (COVID-19) and no criteria for hospitalisation.

    Authors: Alexandre Duvignaud, Edouard Lhomme, Thierry Pistone, Racha Onaisi, Rémi Sitta, Valérie Journot, Duc Nguyen, Nathan Peiffer-Smadja, Antoine Crémer, Stéphane Bouchet, Thomas Darnaud, Delphine Poitrenaud, Lionel Piroth, Christine Binquet, Jean-François Michel, Benjamin Lefèvre…

    Citation: Trials 2020 21:846

    Content type: Letter

    Published on:

  47. We investigate the effects of Ginger, compared to the usual therapeutic regimen on clinical manifestations and paraclinical features in patients with confirmed COVID-19 that are moderately ill.

    Authors: Omid Safa, Mehdi Hassaniazad, Mehdi Farashahinejad, Parivash Davoodian, Habib Dadvand, Soheil Hassanipour and Mohammad Fathalipour

    Citation: Trials 2020 21:841

    Content type: Letter

    Published on:

  48. Primary objectives

    Authors: Maike Janssen, Ulrike Schäkel, Carine Djuka Fokou, Johannes Krisam, Jacek Stermann, Katharina Kriegsmann, Isabella Haberbosch, Jan Philipp Novotny, Stefan Weber, Maria Vehreschild, Martin Bornhäuser, Lars Bullinger, Michael Schmitt, Tobias Liebregts, Peter Dreger, Hanns-Martin Lorenz…

    Citation: Trials 2020 21:828

    Content type: Letter

    Published on:

  49. We aimed to test our hypothesis that additional administration of traditional Japanese (Kampo) medicine, kakkonto (kakkon-to: KT) and shosaikotokakikyosekko (sho-saiko-to-ka-kikyo-sekko: SSKKS), is more effect...

    Authors: Shin Takayama, Takao Namiki, Takashi Ito, Ryutaro Arita, Hajime Nakae, Seiichi Kobayashi, Tetsuhiro Yoshino, Tomoaki Ishigami, Koichiro Tanaka, Mosaburo Kainuma, Kotaro Nochioka, Airi Takagi, Masaru Mimura, Takuhiro Yamaguchi and Tadashi Ishii

    Citation: Trials 2020 21:827

    Content type: Letter

    Published on:

  50. Early reports indicate that COVID-19 may require intensive care unit (ICU) admission in 5–26% and overall mortality can rise to 11% of the recognised cases, particularly affecting the elderly. There is a lack ...

    Authors: Bálint Erőss, Zsolt Molnár, Zsolt Szakács, Noémi Zádori, Lajos Szakó, Szilárd Váncsa, Márk Félix Juhász, Klementina Ocskay, Nóra Vörhendi, Katalin Márta, Andrea Szentesi, Andrea Párniczky, Péter J. Hegyi, Szabolcs Kiss, Mária Földi, Fanni Dembrovszky…

    Citation: Trials 2020 21:809

    Content type: Study protocol

    Published on: